Features of Top Medical Device Companies

HART CEO David Green on the transformative potential for regenerative medicine

September 3, 2014 by Brad Perriello

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

YYmeta

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

August 15, 2014 by Arezu Sarvestani

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Alliqua Biomedical (NSDQ:ALQA) CEO Dave Johnson hasn't been at the helm very long, but the company has seen a major turnaround during his time.

Podcast: Medtech legends and leaders on the state of medical device innovation

August 6, 2014 by Brian Johnson

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

On July 15, 2014, MassDevice.com brought together 4 senior medtech leaders to discuss the future of the medical device industry at our DeviceTalks Boston event.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

CardioMEMS' 11-year payoff worth the wait for Boston Millennia Partners

July 31, 2014 by Brian Johnson

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

The CardioMEMS story didn't end when St. Jude Medical (NYSE:STJ) acquired the Georgia-based company in June, paying $375 million for the stake it didn’t already own, valuing the implantable heart failure monitor company at $463 million total.

Podcast: CEO Brian Concannon on the past and future for Haemonetics at MassDevice.com's DeviceTalks

July 23, 2014 by Brian Johnson

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

More than a year ago, Haemonetics (NYSE:HAE) launched a major restructuring effort, moving nearly 300 manufacturing jobs out of the country in an effort to cut between $35 million and $40 million by fiscal 2018.

The cuts were painful, not only for the 42-year-old blood management company and its workers, but for CEO Brian Concannon, who grew up only a stone's throw from the company's headquarters in Braintree, Mass.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

July 10, 2014 by Brad Perriello

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

For years the Holy Grail of ophthalmology has been to give patients the ability to see clearly both and near and far distances. Verne Sharma, CEO of Calhoun Vision, thnks his company's light-adjustable lens has reached that goal.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

July 7, 2014 by Arezu Sarvestani

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

Digital health is all the rage in Silicon Valley, especially as consumer technology's biggest players are getting more interested in tracking health and fitness. But for companies like iRhythm, the health side of the equation comes first.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Podcast: Covidien's Enxing Seng talks Medtronic merger, future of medicine at DeviceTalks

July 1, 2014 by Brian Johnson

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

MassDevice.com sat down with Stacy Enxing Seng, executive in residence at Covidien (NYSE:COV), just a week after the company announced it had agreed to be acquired by Medtronic (NYSE:MDT) for $43 billion.

FDA cybersecurity rejections are on the way

June 5, 2014 by Arezu Sarvestani

The FDA is ramping up its cybersecurity labs and may start rejecting insecure technologies sooner than you think.

FDA cybersecurity rejections are on the way

Although the FDA has only recently begun addressing medical device cybersecurity in an official capacity, device makers would do well to take notice that the agency has ramped up its oversight quickly over the last year.

Brian Walsh looks to transcend glaucoma treatment with CyPass micro-stent

June 2, 2014 by Brad Perriello

Transcend Medical CEO Brian Walsh tells MassDevice.com why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma.

Brian Walsh looks to transcend glaucoma treatment with micro-stent

Until recently, the treatment for glaucoma – a group of diseases that cause pressure within the eyeball – consisted of several options, none of them ideal. Patients could opt for medicines, either oral or via eyedrops, to lower eye pressure. A surgical option that in essence creates a drain in the eyeball for ocular fluid is also available, as is a procedure call laser trabeculoplasty that also creates a drainage pathway.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp